Comparative Pharmacology
Head-to-head clinical analysis: QULIPTA versus UBRELVY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QULIPTA versus UBRELVY.
QULIPTA vs UBRELVY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
QULIPTA (atogepant) is a calcitonin gene-related peptide (CGRP) receptor antagonist. It competitively blocks the binding of CGRP to its receptor, thereby inhibiting CGRP-mediated vasodilation and pain transmission involved in migraine pathophysiology.
Calcitonin gene-related peptide (CGRP) receptor antagonist; blocks CGRP-mediated vasodilation and nociception.
10 mg orally once daily
100 mg orally once, may repeat once after at least 2 hours if needed; maximum 200 mg per 24 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 21 hours, supporting once-daily dosing.
Terminal elimination half-life is approximately 50 hours, supporting once-daily dosing.
Approximately 60% of the dose is excreted in feces (as unchanged drug and metabolites) and 40% in urine (primarily as metabolites, with <1% unchanged).
Primarily hepatic metabolism via CYP3A4, with 42% of dose excreted in feces (6% unchanged) and 26% in urine (1% unchanged).
Category C
Category C
CGRP Antagonist
CGRP Antagonist